MedPath

SpyGlass Pharma Completes Enrollment in Phase I/II Glaucoma Drug Delivery Study

• SpyGlass Pharma has finished enrolling patients in its Phase I/II clinical trial evaluating its drug delivery platform for glaucoma and ocular hypertension. • The platform delivers bimatoprost over three years and is implanted during routine cataract surgery, potentially expanding glaucoma treatment options. • The company is preparing for an End of Phase II meeting with the FDA to discuss advancing the platform into Phase III pivotal studies. • SpyGlass's technology aims to improve glaucoma care by integrating treatment into cataract procedures, enhancing adoption among surgeons.

SpyGlass Pharma has announced the completion of enrollment in its Phase I/II clinical trial (NCT06120842) assessing its novel drug delivery platform for patients suffering from glaucoma or ocular hypertension. The platform is designed to provide a sustained release of bimatoprost, aiming to lower intraocular pressure (IOP) for up to three years following implantation during routine cataract surgery.
The completion of enrollment marks a significant step for SpyGlass Pharma as it seeks to address the challenges of chronic eye conditions like glaucoma, a leading cause of vision loss worldwide. The innovative platform aims to improve patient compliance and outcomes by integrating glaucoma treatment directly into cataract procedures.

Potential to Transform Glaucoma Treatment

According to SpyGlass Pharma, the drug delivery platform has the potential to transform glaucoma treatment by enabling all cataract surgeons to treat glaucoma during routine cataract procedures.
"The SpyGlass technology continues to demonstrate great potential for improving care in glaucoma patients undergoing routine cataract surgery," said Malik Kahook, M.D., co-founder of SpyGlass Pharma. "As the SpyGlass platform is implanted using standard surgical techniques, it could significantly expand the integration of glaucoma treatment into routine cataract procedures. This could enhance adoption across a broad spectrum of surgeons and practices, setting our platform apart from currently available glaucoma interventions."

Study Design and Future Plans

The Phase I/II study is a randomized, multi-center, controlled clinical trial. SpyGlass Pharma intends to release further data from this study, as well as from its first-in-human study, which recently published 18-month data. The company is also preparing to engage with the FDA in an End of Phase II meeting to discuss the pathway to Phase III pivotal trials.

About SpyGlass Pharma

SpyGlass Pharma is focused on developing the world’s first IOL-mounted, controlled-release drug delivery platform capable of delivering multiple years of therapy. The company's technology was initially developed at the University of Colorado School of Medicine and has garnered support from investors including New Enterprise Associates (NEA), RA Capital, Vensana Capital, Samsara BioCapital, and Vertex Ventures HC.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

SpyGlass Pharma Completes Enrollment in Phase I/II Glaucoma Drug Delivery Study

SpyGlass Pharma has finished enrolling patients in its Phase I/II clinical trial for a novel drug delivery platform targeting glaucoma and ocular hypertension.
The platform delivers bimatoprost over three years, aiming to reduce intraocular pressure (IOP) via a sustained-release mechanism during cataract surgery.

SpyGlass Pharma Completes Phase I/II Trial Enrollment for Glaucoma Drug Delivery Platform

SpyGlass Pharma has finished enrolling patients in its Phase I/II clinical trial for a novel drug delivery platform designed to treat glaucoma and ocular hypertension.
The platform delivers bimatoprost over three years during routine cataract surgery, aiming to reduce intraocular pressure (IOP) effectively.

Phaxiam Therapeutics' Phage Therapy Receives FDA Clearance for Phase II PJI Trial

Phaxiam Therapeutics received FDA clearance for its Phase II GLORIA study, evaluating phage therapy for Staphylococcus aureus-related Prosthetic Joint Infections (PJI).
The GLORIA study is a multicenter, randomized, placebo-controlled trial assessing the efficacy of Phaxiam's anti-S. aureus phages in combination with antibiotics for PJI treatment.

FDA Approves Phaxiam Therapeutics' Phase II Trial for Staphylococcus aureus Prosthetic Joint Infections

Phaxiam Therapeutics received FDA approval for its Investigational New Drug (IND) application to conduct a Phase II study, named 'GLORIA', targeting osteoarticular prosthesis infections (PJI) caused by *Staphylococcus aureus*.
The GLORIA study will enroll 100 patients with hip or knee PJI undergoing open surgical debridement (DAIR), evaluating Phaxiam's anti-*S. aureus* phages in combination with antibiotics versus placebo plus antibiotics.

Phaxiam Therapeutics Receives FDA Clearance for Phase II Phage Therapy Study in Prosthetic Joint Infections

Phaxiam Therapeutics received FDA clearance for its Phase II GLORIA study, evaluating phage therapy for Staphylococcus aureus-related Prosthetic Joint Infections (PJI).
The GLORIA study is a multicenter, randomized, placebo-controlled trial that will enroll 100 PJI patients undergoing open surgical debridement.

Phaxiam Therapeutics Receives FDA Clearance for Phase II Phage Therapy Study in Prosthetic Joint Infections

Phaxiam Therapeutics received FDA clearance to begin its Phase II GLORIA study, which will assess phage therapy for Staphylococcus aureus-related Prosthetic Joint Infections (PJI).
The GLORIA study is a multicenter, randomized, placebo-controlled trial evaluating anti-S. aureus phages in combination with antibiotics for PJI patients undergoing open surgical debridement.

Scilex Gains FDA Clarity on SP-103 Path to NDA for Chronic Neck Pain

Scilex Holding announced a successful end-of-Phase II meeting with the FDA for SP-103, a high-concentration lidocaine formulation targeting chronic neck pain.
The FDA has provided a clear pathway forward to a New Drug Application (NDA) for SP-103 upon successful completion of Phase III trials.

Scilex's SP-103 Lidocaine Topical System Receives Positive FDA Feedback for Chronic Neck Pain

Scilex Pharmaceuticals gains FDA agreement on NDA path for SP-103, a triple-strength lidocaine topical system, after a successful Phase II meeting.
SP-103 targets chronic neck pain associated with muscle spasms, with potential peak sales projected at $1.2 billion annually.

Phaxiam Therapeutics Advances Phage Therapy with Phase 2 Trial for Staphylococcus aureus Vascular Graft Infections

Phaxiam Therapeutics' PHAGOSCARPA, a phase 2 study, will assess anti-S. aureus phages for treating extra-cavitary vascular graft implant infections.
The trial, involving 80 patients across 27 French centers, aims to improve outcomes where mortality rates range from 10-25% within 30 days.

Nanoscope Therapeutics to Advance MCO-010 for Stargardt Disease to Phase 3 Trial Following FDA Meeting

Nanoscope Therapeutics' MCO-010 gene therapy is set to advance to a Phase 3 registrational trial for Stargardt Macular Degeneration after a productive meeting with the FDA.
The FDA has provided input on the Phase 3 trial design, which will assess MCO-010's safety and efficacy using best-corrected visual acuity as the primary endpoint.

Reference News

[1]
SpyGlass Pharma Completes Enrollment in Phase I/II Study of its Promising Long-Term ...
biospace.com · Nov 19, 2024

SpyGlass Pharma completes enrollment in Phase I/II clinical trial for its Drug Delivery Platform, designed to deliver bi...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy